electroCore,

electroCore, Receivables Turnover

The Receivables Turnover Ratio of electroCore, (ECOR) as of Oct 17, 2026 is 18.42. In the previous year, Receivables Turnover Ratio was 22.36 — a change of -17.60% (lower).

Receivables Turnover

18.42

YoY

-17.60%

Last updated:

Receivables Turnover Ratio of electroCore, is 2024 18.42 . Receivables Turnover Ratio of electroCore, was 2023 22.36 . It decreases by -17.60% lower compared to the previous year.

The electroCore, Receivables Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables Turnover
Date
Receivables Turnover
Jan 1, 2017
8.11 USD
Jan 1, 2018
3.68 USD
Jan 1, 2019
4.78 USD
Jan 1, 2020
12.95 USD
Jan 1, 2021
12.39 USD
Jan 1, 2022
21.48 USD
Jan 1, 2023
22.36 USD
Jan 1, 2024
18.42 USD
The electroCore, Receivables Turnover history
YEARReceivables TurnoverYoY
18.42-17.60%
22.36+4.08%
21.48+73.38%
12.39-4.32%
12.95+170.84%
4.78+29.99%
3.68-54.68%
8.11-36.14%
12.71—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

electroCore, Stock analysis

What does electroCore, do? electroCore, Inc. is a medical device company based in Basking Ridge, New Jersey, operating in the Health Care sector. The company focuses on non-invasive vagus nerve stimulation (nVNS) therapy, offering a hand-held device called gammaCore. This device provides non-drug treatment for adults experiencing episodic cluster and migraine pain. electroCore's technology targets primary headaches, including migraine and cluster headache, as well as related chronic conditions such as gastric motility disorders, psychiatric issues, sleep disorders, and pain disorders. The company went public via an IPO on June 22, 2018, and currently employs 83 full-time staff. Its headquarters are located in Basking Ridge, and it operates within the Health Care industry. electroCore's primary product, gammaCore, is designed for non-invasive cervical vagus nerve stimulation, aiming to address neurological, psychiatric, gastroenterological, and respiratory conditions. The company's website is https://www.electrocore.com/. electroCore is listed under the ticker ECOR with ISIN US28531P2020. The firm's commercial stage operations emphasize non-invasive therapeutic solutions without pharmaceutical intervention. electroCore, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about electroCore, stock

Receivables Turnover Ratio of electroCore, is 18.42 in 2024.

Receivables Turnover Ratio of electroCore, changed from 22.36 to 18.42, representing a -17.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Receivables Turnover Ratio electroCore, since 2006 – with annual values, charts, and detailed analysis.

Receivables turnover measures how efficiently a company collects its receivables. Higher turnover indicates faster collection.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Receivables Turnover Ratio's electroCore, with sector peers and the industry average to assess whether it is attractive.

To evaluate Receivables Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Receivables Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — electroCore,

All Key Metrics — electroCore,